Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Lutronic's Action II Petit Lady™ Receives CE Mark Clearance for the Treatment of Vaginal Relaxation Syndrome & Stress Urinary Incontinence
  • USA - English


News provided by

Lutronic Inc.

Jun 23, 2014, 07:55 ET

Share this article

Share toX

Share this article

Share toX

Non-surgical and non-invasive treatment for vaginal rejuvenation
Non-surgical and non-invasive treatment for vaginal rejuvenation

Petit Lady is particularly recommended to menopausal patients, because the mechanism of laser remodelling not only rejuvenates the condition of the vagina but also enhances sexual gratification and better quality of life

Post this

Fremont, CA (PRWEB) June 23, 2014 -- Lutronic, a global leader of lasers and therapeutic devices for aesthetic and medical applications, announced today that Action II Petit Lady™ has received CE mark clearance for treatment of vaginal relaxation syndrome (VRS) and stress urinary incontinence (SUI). VRS is a quite common medical condition described as a loss of the optimal vaginal structure and is usually associated with vaginal child delivery and natural aging. SUI refers to the involuntary loss of control of the bladder and it can occur following some normal activity, such as coughing, sneezing, running, heavy lifting or even just bending over.

Current VRS Treatments include surgical procedures and pharmacological therapies; the surgical options available require long recovery and like pharmacological options may cause unwanted side effects. Clinicians have been looking for a better minimally or non invasive solution that provides short downtimes and low risk of side effects.

Lutronic worked with experienced clinicians to develop a new treatment that meets their patients’ needs. The Action II Petit Lady is a non-surgical, non-invasive and easy to perform laser treatment that enables gynecologists to effectively treat a wide range of vulva-vaginal symptoms and conditions and helps patients solve their most private problems.

“The Petit Lady approach is suggested for females who have vaginal relaxation syndrome but for whom a surgical procedure might not be appropriate because the symptoms are mild and the patient’s concern about pain and downtime. This laser procedure is suitable to be all pied in combination with vaginal muscle reconstruction to obtain a synergetic effect and to achieve better maintenance,” stated Hyung Keun Lee, MD, PhD., Chief director of RIZ Laser Cosmetic Vaginal Surgery Center which is the first clinic specializing in vaginoplasty in Asia. “Petit Lady is particularly recommended to menopausal patients, because the mechanism of laser remodelling not only rejuvenates the condition of the vagina but also enhances sexual gratification and better quality of life.”

This new CE approval enables the Action II Er:YAG laser system to expand its clinical applications and to build on the success of the original Action II device which primarily focused on aesthetic treatments; gaining CE approval for the treatment of scar revision, epidermal benign disorders and epidermal pigment lesions in December 2012.

“Action II Petit Lady is a device that provides a new dimension in Er:YAG laser technology applied to gynecological indications. It has 3 independent operating modes such as the multiple micropulsed mode, the long-pulsed mode up to 1000 ms and a unique Dual mode which allows a deeper secondary thermal effect and controlled heating of the delicate target tissues of the vaginal wall. These improved features also allow for swift wound healing and an excellent tissue tightening effect. The unique patent pending design of the intravaginal scopes provides a more efficient and comfortable procedure.” Stated Mr. S.H. Ko, Lutronic’s international sales director. "The market opportunity for Action II Petit Lady procedure in Europe is substantial and we're looking forward to expanding our presence in Europe,” he added.

Lutronic will initiate the commercial launch of Action II Petit Lady into the EU market through prestige retailers during the third quarter of 2014.

About Action II Petit Lady
The Lutronic Action II Petit Lady is a 360° solution for cosmetic gynecology. The treatment is gentle, simple and fast. The Action II Petit Lady 360° handpiece is specially designed for VRS. It delivers multiple micropulses to the vaginal mucosa to stimulate collagen remodelling and tighten the vaginal canal. The Action II Petit Lady 90º handpiece is intended for SUI, providing an enhanced thermal and shrinkage effect in the endopelvic fascia, ligaments, and mucosal tissue of the anterior vaginal canal.

The robust Action II Petit Lady has a long list of features that support both physician and patient needs.

  • Non-invasive, non-surgical procedure
  • No downtime and little to no risk of bleeding, pain, or scarring
  • Multiple hand-pieces: Petit 360º handpiece, Petit 90º handpiece, & fractional handpiece
  • Easy to manipulate articulated arm
  • Dedicated GUI for Petit Lady mode
  • Multiple modes & 2940 nm Er:YAG laser energy deliver

Previously released outside of the Europe, the Action II Petit Lady is clinically proven in Asia and the Middle East, and has enabled investigators and clinicians to perform many procedures. Action II Petit lady is clinical proven to be efficacious and safe in treating Asian patients; One of the studies, presented at the 34th ASLMS Annual Conference, showed that the unique delivery of the Action II’s Petit 2,940 nm Er:YAG laser energy provided a statistically significant improvement in vaginal relaxation without pain, safety issues, or side effects.

To learn more about the Action II Petit Lady, please visit: http://www.petitlady.net/.

About LUTRONIC
Lutronic, a leading innovator in advanced aesthetic and medical laser and related technology, was established over 17 years ago to bring intuitive, robust, versatile devices that are affordable and efficacious to the worldwide medical community. Committed to improving medicine, Lutronic partners with key opinion leaders to advance science and ensure the efficacy of its systems. All systems are versatile and offer multiple setting and treatment options for customized treatments, which optimize outcomes for a wide variety of conditions and treatments including melasma, tattoo removal, soft tissue incision, vascular lesions, hair removal, wrinkle reduction, skin resurfacing, body/facial contouring, chronic pain and more.

With a focus on physician needs and patient outcomes, Lutronic dedicates time and funding toward the development of devices that offer features and improvements not found in today’s market. Devoting more than 20% of revenues to R&D, Lutronic holds more than 240 intellectual properties including current and pending patents worldwide. With more than 250 employees worldwide, Lutronic has offices in the US, Korea, China, Japan, and Europe, a worldwide network of distributors, and is ever expanding.

To learn more about Lutronic Corp, please visit: http://www.lutronic.com/.

Jennifer Ahn, Lutronic Inc., http://www.lutronic.com, +82 7047146039, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.